Observational studyHaematologica2019
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Open access · goldAbstract readObservational Study
In one paragraph
Observational study in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 76 citations in OpenAlex.
- Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.Haematologica · 2022Trial
- Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.British journal of haematology · 2026Article
- Evolving Therapeutic Algorithms in Chronic Myeloid Leukemia: Integrating Efficacy, Safety, and Survivorship.Biomedicines · 2026Review
- Low-dose dasatinib in second-line therapy or beyond for the treatment of chronic-phase chronic myeloid leukemia: a real-world cohort study.Frontiers in pharmacology · 2026Article
- Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions.European journal of haematology · 2025Review
- Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia.European journal of haematology · 2025Article
- A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.Blood cancer journal · 2024Article
- Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors.Oncology and therapy · 2024Article
- Exploration of treatment-free remission in CML, based on molecular monitoring.Cancer medicine · 2024Review
- Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26Frontiers in pharmacology · 2023Article
- Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings.Frontiers in oncology · 2023Review
- Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review.Journal of blood medicine · 2023Review
- Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice.Frontiers in pharmacology · 2023Article
- Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.Frontiers in pharmacology · 2023Article
- Article
- Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.Annals of hematology · 2022Article
- Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience.Pharmacology research & perspectives · 2022Article
- [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Observational
- Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.American journal of hematology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 20 institutions in 2 countries.
Carmen FavaDepartment of Clinical and Biological Sciences, University of Turin, Orbassano carmen.fava@unito.it.
Giovanna Rege-CambrinDepartment of Clinical and Biological Sciences, University of Turin, Orbassano.
Irene DogliottiDepartment of Clinical and Biological Sciences, University of Turin, Orbassano.
Marco CerranoHematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin.
Paola BerchiallaDepartment of Clinical and Biological Sciences, University of Turin, Orbassano.
Matteo DraganiDepartment of Clinical and Biological Sciences, University of Turin, Orbassano.
Gianantonio RostiInstitute of Hematology "L. & A. Seràgnoli", St. Orsola University Hospital, Bologna.
Fausto CastagnettiInstitute of Hematology "L. & A. Seràgnoli", St. Orsola University Hospital, Bologna.
Gabriele GugliottaInstitute of Hematology "L. & A. Seràgnoli", St. Orsola University Hospital, Bologna.
Bruno MartinoAzienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria.
Carlo Gambacorti-PasseriniUniversity Milano Bicocca, San Gerardo Hospital, Monza.
Elisabetta AbruzzeseHaematology Unit, S. Eugenio Hospital, Rome.
Chiara ElenaHematology Hunit, Fondazione IRCCS Policlinico San Matteo, Pavia.
Patrizia PregnoA.O. Città della Salute e della Scienza di Torino, Turin.
Antonella GozziniSC Terapie Cellulari e Medicina Trasfusionale, AOU Careggi, Florence.
Isabella CapodannoHematology, Azienda Unità Sanitaria Locale -IRCCS, Reggio Emilia.
Micaela BergamaschiDivision of Hematology 1, IRCCS AOU San Martino-IST, Genoa.
Monica CrugnolaDivision of Hematology, University Hospital of Parma, Parma.
Monica BocchiaAzienda Ospedaliera Universitaria, University of Siena, Siena.
Sara GalimbertiHematology Department, University of Pisa, Pisa.
Davide RapezziS.C. Ematologia, ASO S. Croce e Carle, Cuneo.
Alessandra IurloHaematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan.
Daniele CattaneoHaematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan.
Roberto LatagliataDepartment of Cellular Biotechnologies and Hematology, University La Sapienza, Rome.
Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, University La Sapienza, Rome.
Michele CedroneUOC of Hematology, San Giovanni - Addolorata Hospital, Rome.
Marco SantoroHematology Unit, University of Palermo, Palermo.
Mario AnnunziataDivision of Hematology, Ospedale Cardarelli, Naples.
Luciano LevatoDepartment Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro.
Fabio StagnoChair and Hematology Section, Ferrarotto Hospital, Catania.
Francesco CavazziniDepartment of Medical Sciences -Haematology and Physiopathology of Haemostasis Section, Ferrara.
Nicola SgherzaDivision of Hematology, IRCCS Ospedale Casa Sollievo Sofferenza, San Giovanni Rotondo.
Valentina GiaiDivision of Haematology, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria.
Luigia LucianoDivision of Hematology - Departments of Clinical Medicine and Surgery, University of Naples Federico II, Naples.
Sabina RussoDepartment of Internal Medicine, AOU Policlinico di Messina, Messina.
Pellegrino MustoIRCCS, Centro Di Riferimento Oncologico Della Basilicata, Rionero in Vulture.
Giovanni CaocciDepartment of Medical Sciences, University of Cagliari, Cagliari.
Federica SoràHematology Department, University Cattolica del Sacro Cuore - Policlinico A. Gemelli, Rome.
Francesco IulianoPresidio Ospedaliero N. Giannetasio - Azienda ASL 3, Rossano.
Francesca LunghiDivision of Haematology and Bone Marrow Transplant, Ospedale San Raffaele IRCCS, Milan.
Giorgina SpecchiaDivision of Haematology with Transplant - Outpatients, Azienda Ospedaliero-Universitaria Policlinico Consorziale di Bari, Bari, Italy.
Fabrizio PaneDivision of Hematology - Departments of Clinical Medicine and Surgery, University of Naples Federico II, Naples.
Dario FerreroHematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin.
Michele BaccaraniInstitute of Hematology "L. & A. Seràgnoli", St. Orsola University Hospital, Bologna.
Giuseppe SaglioDepartment of Clinical and Biological Sciences, University of Turin, Orbassano.
University of Turin · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITUniversity of Naples Federico II · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITAzienda Ospedaliera Pugliese Ciaccio · ITAzienda Ospedaliera San Giovanni Addolorata · ITAzienda Sanitaria Ospedaliera S.Croce e Carle Cuneo · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITAzienda Universitaria Ospedaliera Consorziale - Policlinico Bari · ITCasa Sollievo della Sofferenza · ITCentro di Riferimento Oncologico della Basilicata · ITFerrarotto Hospital · ITIRCCS Ospedale San Raffaele · ITOspedale Antonio Cardarelli · ITOspedale Policlinico San Martino · ITPoliclinico San Matteo Fondazione · ITPresidio Ospedaliero · ITSt. Eugenio Hospital · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TKI than with imatinib (
Indexed as
Safety-Based Drug WithdrawalsAdultDisease ProgressionFemaleHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseMaleMiddle AgedPregnancyProtein Kinase InhibitorsProtein-Tyrosine KinasesRetrospective StudiesTreatment OutcomeImatinib MesylateProtein Kinase InhibitorsProtein-Tyrosine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.